Mylan and Lupin make deal for etanercept biosimilar

INICIO/Noticias Farmacéuticas | Posted 20/07/2018 post-comment0 Post your comment

Indian generics manufacturer Lupin Pharmaceuticals (Lupin) and US-based drugmaker Mylan announced on 28 June 2018 that they had made a deal to commercialize an etanercept biosimilar.


As part of the agreement, Mylan will commercialize Lupin’s proposed etanercept biosimilar in Europe, Australia, New Zealand, Latin America, Africa and most markets throughout Asia. Lupin will receive an up-front payment of US$15 million and potential commercial milestones together with an equal share in net profits of the product.

Etanercept is a biological drug that treats autoimmune diseases by inhibiting tumour necrosis factor (TNF); a soluble inflammatory cytokine. It is indicated for the treatment of rheumatoid, juvenile rheumatoid and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis.

Lupin successfully completed a phase III clinical trial for its candidate etanercept biosimilar (YLB113) in February 2018 [1]. The company had the application for YLB113 accepted for regulatory review by the European Medicines Agency in May 2018 [2]. The company also announced in May 2018 that YL Biologics had submitted a new drug application (NDA) in Japan for YLB113 in March 2018 [2]. YL Biologics is a joint venture between Lupin and Japanese firm Yoshindo [3].

Related articles
Mylan and Fujifilm Kyowa Kirin Biologics partner on adalimumab biosimilar

Biosimilar deals for Hikma and Lupin

1. GaBI Online - Generics and Biosimilars Initiative. Yoshindo and Lupin’s etanercept biosimilar completes trials []. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Jul 20]. Available from:
2. GaBI Online - Generics and Biosimilars Initiative. Etanercept biosimilars submitted to EMA and launched in Japan []. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Jul 20]. Available from:
3. GaBI Online - Generics and Biosimilars Initiative. Lupin and Yoshindo start biosimilars joint venture []. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Jul 20]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2018 Pro Pharma Communications International. All Rights Reserved.

Source: Mylan

comment icon Comments (0)
Post your comment
Related content
El recorrido del biológico de continuación Pectuna (pertuzumab) en Irán
Cancer Cell V13I20
INICIO/Noticias Farmacéuticas Posted 29/02/2024
Fiocruz y Pfizer firman un acuerdo para el genérico de Xeljanz
Remicade V13F28
INICIO/Noticias Farmacéuticas Posted 30/01/2024
Genfar: La nueva marca de genéricos de Eurofarma en América Latina
10 AA008993
INICIO/Noticias Farmacéuticas Posted 12/12/2023
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010